Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
- Registration Number
- NCT00658255
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to compare the therapeutic effects of formoterol in Symbicort with formoterol in Oxis Turbuhaler for the treatment of adults with stable asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 175
Inclusion Criteria
- At least 18 years of age
- Diagnosis of asthma and baseline lung function tests as determined by the protocol
- Required and received treatment with inhaled corticosteroids within timeframe and doses specified in the protocol
Exclusion Criteria
- Severe asthma
- Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 2 formoterol - 1 budesonide/formoterol -
- Primary Outcome Measures
Name Time Method Average FEV1 during 12 hours Once a week for 5 weeks during treatment period
- Secondary Outcome Measures
Name Time Method Urine levels of formoterol in 2 different formulations Once a week (12 hour urine collection) for 5 weeks during treatment period Safety profiles of formoterol in 2 different formulations Once a week for 5 weeks during treatment period